Dermatophagoides pteronyssinus

DB10401ApprovedInvestigationalAllergenicsStandardized Insect Allergenic Extract

Dermatophagoides pteronyssinus is an extract from Dermatophagoides pteronyssinus used in allergy testing. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.

Mechanism
Curator reviewed
Primary indication
Dermatophagoides pteronyssinus is indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or...Curator reviewed · 2 structured indications
First approval
Canada, 1997 · United States, 1986
Also known as
AE-mite, dermatophagoides pteronyssinus · Dermatophagoides pteronyssinus whole · European house dust mite · European house dust mite extract · House dust mite extract, dermatophagoides pteronyssinus
Brand names
  • Acarizax
  • Odactra

Resolves to

What you can answer from here — as of May 03, 2025

11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
5ContraindicationsEach with its own population and attribute set
Sign in
176Marketed productsAcross 5 countries and 16 labellers
Sign in
1ATC codeIncluding every combination product, plus 8 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Dermatophagoides pteronyssinus, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account